Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range ...

We recently compiled a list of the 15 Stocks That Will Go to The Moon According to Analysts. In this article, we are going to ...

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Summit Therapeutics (NASDAQ:SMMT – Get Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC ...

Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug ...

We recently published a list of 10 Stocks Drop The Most Amid Investor Caution. In this article, we are going to take a look ...

Q4 2024 Earnings Call Transcript February 24, 2025 Operator: Good morning and welcome to Summit Therapeutics Fourth Quarter ...

Florida, USA-based Summit Therapeutics saw its share rise 6.2% to $23.50 pre-market on the news of a clinical trial ...

Summit Therapeutics Inc (SMMT) reports a robust cash reserve and debt-free status, while advancing key clinical trials and ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that its partner on ivonescimab, Summit Therapeutics Inc. (NASDAQ: SMMT) has entered into a clinical trial collaboration with Pfizer ...

Summit Therapeutics established a clinical trial collaboration with Pfizer to develop ivonescimab for NSCLC and solid tumors.

Compass Therapeutics (CMPX) stock was up 8% in afternoon trading Monday after Guggenheim initiated coverage of the stock with a buy rating ahead of upcoming data. Read more here.